Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Amgen and Roche to develop second-generation G-CSF; Amgen reacquires rights

18 Jun 2014

Executive Summary

Amgen and Roche will develop a second-generation G-CSF (granulocyte colony-stimulating factor) product for Europe and extend until 2010 their 1988 deal for sales of Neupogen, the original version.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By